EIGR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 Apr 2024 @ 16:00):

Stats
Today's Volume	129 682
Average Volume	118 095
Market Cap	2.55M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-5.40 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0110 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-02	Kayne Richard A	Buy	23 398	Common Stock
2023-11-01	Kayne Richard A	Buy	100 000	Common Stock
2023-10-31	Kayne Richard A	Buy	130 509	Common Stock
2023-10-31	Kayne Richard A	Buy	12 345	Common Stock
2023-10-31	Kayne Richard A	Buy	11 987	Common Stock

INSIDER POWER
57.32
Last 89 transactions
Buy: 3 414 696 \| Sell: 449 818

Volume Correlation

Long: -0.16 (neutral)

Short: 0.36 (neutral)

Signal:(46.894) Neutral

Eiger BioPharmaceuticals Correlation

10 Most Positive Correlations
STER	0.953
INCR	0.94
RUBY	0.937
JAGX	0.936
PRAX	0.935
AGLE	0.934
DIBS	0.934
EMBK	0.93
RMRM	0.929
CCSI	0.926

10 Most Negative Correlations
LWAC	-0.921
SGEN	-0.914
TIG	-0.912
MTSI	-0.91
TSBK	-0.907
IMRA	-0.905
MPRA	-0.904
SRAC	-0.893
PUCKU	-0.889
MTCR	-0.885

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eiger BioPharmaceuticals Correlation - Currency/Commodity

0.06
( neutral )

-0.44
( neutral )

0.00
( neutral )

0.75
( moderate )

-0.52
( weak negative )

0.42
( neutral )

Eiger BioPharmaceuticals Financials

Annual	2022
Revenue:	$13.48M
Gross Profit:	$11.65M (86.38 %)
EPS:	$-69.74

Q3	2023
Revenue:	$3.21M
Gross Profit:	$3.09M (96.42 %)
EPS:	$-12.20

Q2	2023
Revenue:	$4.64M
Gross Profit:	$4.33M (93.32 %)
EPS:	$-14.02

Q1	2023
Revenue:	$4.12M
Gross Profit:	$4.00M (97.13 %)
EPS:	$-15.48

Financial Reports:

No articles found.

Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.